Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines:international network cohort study from five European countries and the US [PDF]
, 2022 OBJECTIVE: To quantify the comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with use of adenovirus based covid-19 vaccines versus mRNA based covid-19 vaccines.
Burn, Edward +16 more
core +2 more sources
Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
VaccinesThere are varying data concerning the effect of prior anti-vector immunity on the T-cell response induced by immunisation with an identical vectored vaccine containing a heterologous antigen insert. To determine whether prior exposure to ChAdOx1-SARS-CoV2 immunisation (Vaxzevria®) impacts magnitudes of antigen-specific T-cell responses elicited by ...
Davis, C +17 more
openaire +4 more sources
iScience, 2022 Summary: Heterologous SARS-CoV-2 vaccine approaches with a second mRNA-based vaccine have been favored in the recommendations of many countries over homologous vector-based ChAdOx1 nCoV-19 vaccination after reports of thromboembolic events and lower ...
Markus Bauswein +8 more
doaj +1 more source
Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model [PDF]
, 2017 Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel zoonotic virus that causes severe respiratory disease in humans with case fatality rates close to 40%, but for which no vaccines are available.
Bushmaker, T +10 more
core +3 more sources
Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus [PDF]
, 2020 The sequence of non-structural protein NS1 of bluetongue virus (BTV), which contains immunodominant CD8+ T cell epitopes, is highly conserved among BTV serotypes, and has therefore become a major tool in the development of a universal BTV vaccine.
Alonso Ravelo, Ruymán +10 more
core +3 more sources
Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration [PDF]
, 2022 Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them.
Anjum, Afra +24 more
core +1 more source
Frontiers in Immunology, 2022 Evaluation of the safety and immunogenicity of new vaccine platforms is needed to increase public acceptance of coronavirus disease 2019 (COVID-19) vaccines.
Jung Yeon Heo +23 more
doaj +1 more source
Antibody responses after SARS-CoV-2 infection and vaccination in the UK general population [PDF]
, 2023 Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a global pandemic since its first identification in December 2019.
Wei, Jia
core +2 more sources
Inflammatory myositis after ChAdOx1 vaccination [PDF]
The Lancet Rheumatology, 2021 Maramattom, Boby Varkey +3 more
openaire +2 more sources
Neurourology and Urodynamics, EarlyView.ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza +12 more
wiley +1 more source